Use este identificador para citar ou linkar para este item: http://www.alice.cnptia.embrapa.br/alice/handle/doc/1041997
Registro completo de metadados
Campo DCValorIdioma
dc.contributor.authorAGUIRRE, A. de A. R.pt_BR
dc.contributor.authorLOBO, F. P.pt_BR
dc.contributor.authorANDREOTTI, R.pt_BR
dc.date.accessioned2017-03-29T16:11:48Z-
dc.date.available2017-03-29T16:11:48Z-
dc.date.created2016-03-29pt_BR
dc.date.issued2016pt_BR
dc.identifier.citationVeterinary Parasitology, v. 221, p. 30-38, 2016pt_BR
dc.identifier.urihttp://www.alice.cnptia.embrapa.br/alice/handle/doc/1041997pt_BR
dc.descriptionTick infestation may cause several problems including affecting domestic animal health and reducing the production of meat and milk, among others. Resistance to several classes of acaricides have been reported, forcing researchers to search for alternative measures, such as vaccines against ticks, to ensure tick control while having no or at least low negative impacts on the environment and public health. However, the current commercially available vaccines in different strains of Rhipicephalus microplus are reported to be of low efficacy. Fortunately, reverse vaccinology approaches have shown positive results in the new generation of vaccines. On this basis, a synthetic peptide from the ATAQ protein, which is present in the gut and Malpighi tubes of R. microplus, was synthesized. The ATAQ proteins were isolated, characterized and sequenced from several species of the genus Rhipicephalus. The alignment showed 93.3% identity among DNA sequences of ATAQs from these species. Because of this, immunization trials with this peptide were conducted on mice, rabbits and cattle to evaluate the humoral immune response and the efficacy against Rhipicephalus sanguineus in addition to R. microplus. Based on recent results, we conclude that reverse vaccinology is a promising approach because it is more accurate and faster than conventional methods in the detection of potential antigens to use in anti-tick vaccines. It is not only applicable against R. microplus but also against tick species that play important roles in spreading other diseases. ATAQ proteins should be considered as the antigen in new trials to develop a multi-antigenic vaccine. Although these peptides behave as hapten and are not able to be recognized by the immune system on its own, using carriers and adjuvants helps its presentation and induces strong immune responses. Furthermore, an efficiency of 35% reduction in overall life cycle parameters was reported for R. microplus (98% for ELISA responder animals) and 47% for R. sanguineus. Although not yet enough to prevent the environment to infestation of ticks, this still constitutes a promising strategy that could be applied to integrated measures on tick control and in new research that develops anti-tick vaccines.pt_BR
dc.language.isoengeng
dc.rightsopenAccesseng
dc.subjectReverse vaccinologypt_BR
dc.subjectATAQpt_BR
dc.subjectSynthetic peptidept_BR
dc.titleDesign of the ATAQ peptide and its evaluation as an immunogen to develop a Rhipicephalus vaccine.pt_BR
dc.typeArtigo de periódicopt_BR
dc.date.updated2017-03-29T16:11:48Zpt_BR
dc.subject.nalthesaurusImmunizationpt_BR
dc.subject.nalthesaurusRhipicephalus micropluspt_BR
dc.subject.nalthesaurusRhipicephalus sanguineuspt_BR
riaa.ainfo.id1041997pt_BR
riaa.ainfo.lastupdate2017-03-28pt_BR
dc.contributor.institutionANDRÉ DE ABREU RANGEL AGUIRRE, FAMEZ/UFMS; FRANCISCO PEREIRA LOBO, CNPTIA; RENATO ANDREOTTI E SILVA, CNPGC.pt_BR
Aparece nas coleções:Artigo em periódico indexado (CNPGC)

Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
DesignoftheATAQpeptideanditsevaluation.pdf1,42 MBAdobe PDFThumbnail
Visualizar/Abrir
Mostrar registro simples do item Visualizar estatísticas

FacebookTwitterDeliciousLinkedInGoogle BookmarksMySpace